Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gilead Starts China Phase III Trial of Remdesivir in Coronavirus Patients

publication date: Feb 4, 2020

Gilead Sciences, working together with China authorities, has started a China trial of its antiviral remdesivir as a treatment for 2019-nCoV coronavirus. The trial will enroll 270 patients and be based in the China-Japan Friendship Hospital in Beijing. It is a Phase III randomized, double-blind, placebo-controlled multicenter study that will evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV infections. Researchers expect to complete the trial on April 27. Gilead said remdesivir has previously shown efficacy in models of the MERS and SARS coronaviruses. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.